https://staging.lamerie.com/reports/ 2026-03-09T12:13:34+00:00 https://staging.lamerie.com/report/vectorized-antibodies-by-in-vivo-expression-of-dna-or-rna-a-competitive-business-stakeholder-technology-and-pipeline-analysis-from-an-industry-perspective/ 2026-03-09T12:13:34+00:00 https://staging.lamerie.com/report/2025-sales-of-therapeutic-antibodies-proteins-biosimilars-gene-cell-therapy-and-therapeutic-rna-copy/ 2026-03-09T12:13:14+00:00 https://staging.lamerie.com/report/2024-sales-of-therapeutic-antibodies-proteins-biosimilars-gene-cell-therapy-and-therapeutic-rna/ 2026-03-09T12:10:05+00:00 https://staging.lamerie.com/report/pipeline-of-muc16-targeted-immunotherapeutics/ 2025-11-10T10:06:37+00:00 https://staging.lamerie.com/report/pipeline-of-muc1-targeted-immunotherapeutics/ 2025-11-07T10:49:36+00:00 https://staging.lamerie.com/report/pipeline-of-cdh6-targeted-immunotherapeutics/ 2025-11-07T10:47:56+00:00 https://staging.lamerie.com/report/tslp-inhibitors-and-tslp-receptor-antagonists-a-competitor-analysis/ 2025-10-27T13:05:45+00:00 https://staging.lamerie.com/report/competitor-analysis-psma-targeted-therapy-radiodiagnostics/ 2025-10-27T13:04:24+00:00 https://staging.lamerie.com/report/fibroblast-activated-protein-fap-targeted-therapy-a-competitor-analysis/ 2025-10-27T13:03:03+00:00 https://staging.lamerie.com/report/folate-receptor-alpha-fr%ce%b1-targeted-therapy-a-competitor-analysis/ 2025-10-27T13:01:19+00:00 https://staging.lamerie.com/report/dll3-targeted-immunotherapy-a-competitor-analysis/ 2025-10-27T12:26:04+00:00 https://staging.lamerie.com/report/b7-h3-targeted-immunotherapy-a-competitor-analysis/ 2025-10-27T12:23:56+00:00 https://staging.lamerie.com/report/glypican-3-gpc3-targeted-therapy-a-competitor-analysis/ 2025-10-27T12:22:14+00:00 https://staging.lamerie.com/report/tl1a-inhibitors-dr3-antagonists-a-competitor-analysis/ 2025-10-27T12:19:00+00:00 https://staging.lamerie.com/report/pipeline-of-steap1-and-steap2-targeted-immunotherapies/ 2025-10-16T14:10:32+00:00 https://staging.lamerie.com/report/pipeline-of-claudin-18-2-targeted-immunotherapy/ 2025-10-16T14:01:39+00:00 https://staging.lamerie.com/report/pipeline-of-pd-l1-x-4-1bb-cd137-bispecific-antibodies/ 2025-09-24T11:51:22+00:00 https://staging.lamerie.com/report/pipeline-of-cd47-and-sirp-alpha-targeted-immunotherapy/ 2025-09-23T16:41:32+00:00 https://staging.lamerie.com/report/pipeline-of-complement-c5-inhibitors-c5-receptor-antagonists/ 2025-09-22T12:31:57+00:00 https://staging.lamerie.com/report/pipeline-of-interleukin-6-il-6-receptor-antagonists-and-il6-inhibitors/ 2025-09-09T11:12:40+00:00 https://staging.lamerie.com/report/pipeline-of-napi2b-targeted-immunotherapies/ 2025-09-09T11:01:09+00:00 https://staging.lamerie.com/report/pipeline-of-cd40-agonists-and-cd40-l-antagonists/ 2025-09-09T07:48:08+00:00 https://staging.lamerie.com/report/pipeline-of-cd73-inhibitors/ 2025-09-08T09:27:46+00:00 https://staging.lamerie.com/report/pipeline-of-igf-1r-and-igf-1-targeted-immunotherapy/ 2025-09-05T09:51:39+00:00 https://staging.lamerie.com/report/degrader-antibody-conjugates-2024-a-landscape-analysis-of-stakeholders-technologies-pipeline-and-partnering-from-an-industry-perspective/ 2025-09-04T13:09:06+00:00 https://staging.lamerie.com/report/pipeline-review-of-customer-selected-targeted-immunotherapies-pre-scoped-competitor-analysis/ 2025-09-04T13:08:48+00:00 https://staging.lamerie.com/report/pipeline-of-fcrn-targeted-therapies/ 2025-09-03T09:57:08+00:00 https://staging.lamerie.com/report/pipeline-of-klk2-targeted-immunotherapies/ 2025-08-31T08:12:25+00:00 https://staging.lamerie.com/report/pipeline-of-tissue-factor-targeted-immunotherapies/ 2025-08-27T15:17:57+00:00 https://staging.lamerie.com/report/pipeline-of-cd38-targeted-immunotherapies/ 2025-08-26T11:49:52+00:00 https://staging.lamerie.com/report/pipeline-of-trop-2-targeted-immunotherapies/ 2025-08-26T10:37:45+00:00 https://staging.lamerie.com/report/pipeline-of-nectin-4-targeted-immunotherapies/ 2025-08-26T09:19:48+00:00 https://staging.lamerie.com/report/pipeline-of-ccr8-targeted-immunotherapies/ 2025-08-20T08:44:05+00:00 https://staging.lamerie.com/report/pipeline-of-epcam-targeted-immunotherapies/ 2025-08-19T08:20:06+00:00 https://staging.lamerie.com/report/pipeline-of-c-met-targeted-immunotherapies/ 2025-08-19T07:23:31+00:00 https://staging.lamerie.com/report/pipeline-of-her3-targeted-immunotherapies/ 2025-08-19T07:23:03+00:00 https://staging.lamerie.com/report/pipeline-of-mesothelin-targeted-immunotherapies/ 2025-08-18T16:07:48+00:00 https://staging.lamerie.com/report/pipeline-of-b7-h4-targeted-immunotherapies/ 2025-08-18T16:07:18+00:00 https://staging.lamerie.com/report/target-evaluation-for-drug-discovery-pre-scoped-premium-evaluation/ 2025-08-15T09:49:07+00:00 https://staging.lamerie.com/wp-content/uploads/2025/08/Image-03.png https://staging.lamerie.com/report/gprc5d-targeted-therapy-target-expression-profile-safety-efficacy-of-drug-modalities-pipeline-review-and-competitive-landscape-analysis/ 2025-08-14T10:58:28+00:00 https://staging.lamerie.com/report/ror1-targeted-therapy-target-expression-profile-safety-efficacy-of-drug-modalities-pipeline-review-and-competitive-landscape-analysis/ 2025-08-14T10:57:06+00:00 https://staging.lamerie.com/report/target-evaluation-for-drug-discovery-pre-scoped-basic-evaluation/ 2025-08-11T09:22:27+00:00 https://staging.lamerie.com/wp-content/uploads/2025/08/Image-01-1.png https://staging.lamerie.com/report/target-evaluation-for-drug-discovery-pre-scoped-standard-evaluation/ 2025-08-11T09:22:00+00:00 https://staging.lamerie.com/wp-content/uploads/2025/08/Image-02.png https://staging.lamerie.com/report/masked-antibodies-cytokines-as-prodrugs-a-landscape-analysis-of-stakeholders-technologies-pipelines-business-and-financing-from-an-industry-perspective/ 2025-08-09T08:42:21+00:00 https://staging.lamerie.com/report/pd-1-x-vegf-and-pd-l1-x-vegf-bispecific-antibodies-a-business-pipeline-and-competitor-analysis-from-an-industry-perspective/ 2025-08-09T08:41:34+00:00 https://staging.lamerie.com/report/cadherin-17-a-target-opportunity-to-develop-effector-enhanced-drug-modalities/ 2025-08-09T08:40:32+00:00 https://staging.lamerie.com/report/claudin-6-cadherin-17-ror1-and-gprc5d-targeted-therapies-target-expression-profile-safety-efficacy-of-drug-modalities-pipeline-review-and-competitive-landscape-analysis/ 2025-08-09T08:39:22+00:00 https://staging.lamerie.com/report/claudin-6-a-target-opportunity-to-develop-effector-enhanced-drug-modalities/ 2025-08-09T08:38:23+00:00 https://staging.lamerie.com/report/2023-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics/ 2025-03-09T11:43:16+00:00 https://staging.lamerie.com/report/claudin-18-2-targeted-immunotherapy-a-landscape-analysis-of-stakeholders-drug-modalities-pipeline-and-business-opportunities-from-an-industry-perspective/ 2025-02-18T17:10:45+00:00 https://staging.lamerie.com/report/car-m-industry-landscape-analysis-chimeric-antigen-receptor-macrophage-car-m-stakeholders-technologies-pipeline-partnering-and-financing/ 2024-06-30T09:29:39+00:00 https://staging.lamerie.com/report/targeted-protein-degradation-by-proteasomal-lysosomal-autophagy-pathways-2022-an-industry-landscape-analysis-of-stakeholders-technologies-pipeline-partnering-and-financing/ 2024-03-07T13:51:46+00:00 https://staging.lamerie.com/report/rna-targeted-novel-drug-modalities-based-on-rna-editing-epitranscriptomics-direct-rna-targeting-splicing-modulation-translation-regulation-lncrna-regrna-targeting-more-a-landscape-analysis/ 2024-03-03T13:37:17+00:00 https://staging.lamerie.com/report/2022-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics-copy/ 2024-03-03T13:36:11+00:00 https://staging.lamerie.com/report/vectorized-antibodies-for-in-vivo-expression-by-dna-and-mrna-a-landscape-analysis-of-stakeholders-technologies-targets-business-and-financing-from-an-industry-perspective/ 2023-02-10T09:31:48+00:00 https://staging.lamerie.com/report/2021-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics/ 2023-02-10T09:30:43+00:00 https://staging.lamerie.com/report/targeted-protein-degradation-by-novel-protacs-and-molecular-glues-2020-a-landscape-analysis-of-companies-technologies-targets-investors-and-partners-from-an-industry-perspective/ 2022-03-06T16:33:03+00:00 https://staging.lamerie.com/report/rna-targeted-small-molecules-2019-a-landscape-analysis-of-companies-technologies-targets-investors-and-partners-from-an-industry-perspective/ 2021-12-14T08:52:32+00:00 https://staging.lamerie.com/report/2020-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics/ 2021-06-30T11:58:23+00:00 https://staging.lamerie.com/report/blockbuster-biologics-2019-sales-of-recombinant-therapeutic-antibodies-proteins/ 2021-03-12T09:19:53+00:00 https://staging.lamerie.com/report/t-cell-nk-cell-engaging-bispecific-antibodies-2019-a-business-stakeholder-technology-and-pipeline-analysis/ 2020-11-10T10:04:41+00:00 https://staging.lamerie.com/report/intracellular-targets-made-druggable-by-tcr-like-antibodies-tcr-fusion-proteins-cell-penetrating-biologics-2018-an-industry-analysis-of-technologies-stakeholders-deals-trends/ 2020-06-01T11:00:23+00:00 https://staging.lamerie.com/report/tcr-engineered-t-cell-therapy-2018-an-industry-analysis-of-technologies-pipelines-stakeholders-deals/ 2020-05-13T14:08:46+00:00 https://staging.lamerie.com/report/blockbuster-biologics-2018-sales-of-recombinant-therapeutic-antibodies-proteins/ 2019-10-27T11:10:27+00:00 https://staging.lamerie.com/report/blockbuster-biologics-2017-sales-of-recombinant-therapeutic-antibodies-proteins/ 2019-06-05T16:43:02+00:00